Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South India

Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South India

In acute decompensated heart failure (ADHF), diuretic use, the mainstay therapy for congestion, is associated with electrolyte abnormalities and worsening renal function. Vasopressin mediates fluid retention in heart failure. In contrast to diuretics, the vasopressin antagonist tolvaptan may increas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Heart views 2014-01, Vol.15 (1), p.1-5
Hauptverfasser: Patra, Soumya, Kumar, Basant, Harlalka, Kaushal K, Jain, Apoorva, Bhanuprakash, H M, Sadananda, K S, Basappa, Harsha, Santhosh, K, Rajith, K S, Bharathi, K S, Manjunath, C N
Format: Artikel
Sprache:eng
Schlagworte:
Acute decompensated heart failure
Drug therapy
Heart failure
Hyponatremia
Original
Patient outcomes
tolvaptan
vasopressin antagonist
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In acute decompensated heart failure (ADHF), diuretic use, the mainstay therapy for congestion, is associated with electrolyte abnormalities and worsening renal function. Vasopressin mediates fluid retention in heart failure. In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function. Hyponatremia (serum sodium concentration,
ISSN:1995-705X
0976-5123
DOI:10.4103/1995-705X.132136